News & Press

FDA Grants Investigational New Drug Application for TIL Therapy

March 18, 2022

On March 15, the U.S. Food and Drug Administration (FDA) granted Iovance Biotherapeutics, Inc. an Investigational New Drug Application (IND) for IOV-4001, its first genetically modified tumor-infiltrating lymphocytes (TIL) therapy to treat unresectable …

MRF Joins 100 Advocacy Organizations in Support of Cancer Moonshot

March 4, 2022

On February 25, 2022, the American Cancer Society Cancer Action Network (ACS-CAN) and the National Comprehensive Cancer Network (NCCN) sent a joint letter to the Majority and Minority Leaders of both Houses of Congress, indicating strong support for th …

Rare Disease Day in the MRF Community

February 25, 2022

As the MRF observes Rare Disease Day on February 28, 2022, we celebrate the courageous and inspiring members of our community who are living with a rare melanoma subtype. Monique (Acral Lentiginous Melanoma): “It is important for me to be an advocate a …

US Representative Carolyn Maloney to Headline MRF Advocacy Days Plenary

February 23, 2022

WASHINGTON, DC (February 23, 2022) – The Melanoma Research Foundation (MRF) will host nearly 100 advocates during the all-virtual MRF Advocacy Days held March 7-11, 2022. U.S. Representative Carolyn B. Maloney (NY-12) will be featured as the program pl …

Out of the Shadows and “In the Sun”: Reflections from a Melanoma Survivor

February 22, 2022

Guest blog post by Monique Mack, “In the Sun” documentary participant, melanoma survivor and MRF advocate:   My name is Monique Mack, and I am honored to be an advocate for the Melanoma Research Foundation (MRF). I was recently in a documentary called …